Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Vascular Surgery

Free Subscription Articles published in Am Heart J Retrieve available abstracts of 83 articles: HTML format

Single Articles

September 2021
1. NARCISSE DI, Ford CB, Weissler EH, Lippmann SJ, et al
   The association of healthcare disparities and patient-specific factors on clinical outcomes in peripheral artery disease.
   Am Heart J. 2021;239:135-146.
   PubMed     Abstract available
   
   
   June 2021
2. YONG CM, Spinelli KJ, Chiu ST, Jones B, et al
   Cardiovascular Procedural Deferral and Outcomes over COVID-19 Pandemic Phases: A Multi-Center Study.
   Am Heart J. 2021 Jun 25. pii: S0002-8703(21)00167.
   PubMed     Abstract available
   
   
   
3. HU X, Wang Y
   Importance of complete revascularization and surgical techniques when comparing outcomes of CABG with PCI.
   Am Heart J. 2021;236:107-108.
   PubMed    
   
   
   May 2021
4. YERASI C, Case BC, Chezar-Azerrad C, Forrestal BJ, et al
   Cangrelor vs. Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention.
   Am Heart J. 2021 May 4. pii: S0002-8703(21)00115.
   PubMed     Abstract available
   
   
   
5. MADSEN JMM, Jacobsen MRR, Sabbah M, Topal DGG, et al
   Long-Term Prognostic Outcomes and Implication of Oral Anticoagulants in Patients with New-Onset Atrial Fibrillation following ST-Segment Elevation Myocardial Infarction.
   Am Heart J. 2021 May 3. pii: S0002-8703(21)00114.
   PubMed     Abstract available
   
   
   
6. SIDEBOTTOM AC, Miedema MD, Benson G, Vacquier M, et al
   The Impact of a Population-based Prevention Program on Cardiovascular Events: Findings from the Heart of New Ulm Project.
   Am Heart J. 2021 May 3. pii: S0002-8703(21)00112.
   PubMed     Abstract available
   
   
   April 2021
7. SINGH H, Mehta RH, O'Neill W, Kapur NK, et al
   Clinical Features and Outcomes in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction: Early versus Recent Experience with Impella.
   Am Heart J. 2021 Apr 10. pii: S0002-8703(21)00090.
   PubMed     Abstract available
   
   
   March 2021
8. QU J, Du J, Rao C, Chen S, et al
   Effect of a Smartphone-Based Intervention on Secondary Prevention Medication Prescriptions After Coronary Artery Bypass Graft Surgery: The MISSION-1 Randomized Controlled Trial.
   Am Heart J. 2021 Mar 6. pii: S0002-8703(21)00070.
   PubMed     Abstract available
   
   
   
9. FABRIS E, Ten Berg JM, Hermanides RS, Ottervanger JP, et al
   NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: Insight from the On-TIME II trial.
   Am Heart J. 2021;233:78-85.
   PubMed     Abstract available
   
   
   February 2021
10. BATCHELOR WB, Damluji AA, Yong C, Fiuzat M, et al
    DOES STUDY SUBJECT DIVERSITY INFLUENCE CARDIOLOGY RESEARCH SITE PERFORMANCE?: INSIGHTS FROM 2 U.S. NATIONAL CORONARY STENT REGISTRIES.
    Am Heart J. 2021 Feb 23. pii: S0002-8703(21)00035.
    PubMed     Abstract available
    
    
    
11. GE Z, Gao XF, Kan J, Kong XQ, et al
    Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents Guided by either Intravascular Ultrasound or Angiography in Patients with Acute Coronary Syndrome: Rationale and Design of Prospective, Multicent
    Am Heart J. 2021 Feb 20. pii: S0002-8703(21)00053.
    PubMed     Abstract available
    
    
    
12. PILGRIM T, Rothenbuhler M, Siontis GC, Kandzari DE, et al
    Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: a meta-analysis of individual patient data from five randomized trials.
    Am Heart J. 2021 Feb 17. pii: S0002-8703(21)00048.
    PubMed     Abstract available
    
    
    
13. PRABHU KM, Don C, Sayre GG, Kearney KE, et al
    Interventional Cardiologists' Perceptions of Percutaneous Coronary Intervention Quality Measurement and Feedback.
    Am Heart J. 2021 Feb 7. pii: S0002-8703(21)00032.
    PubMed     Abstract available
    
    
    
14. BROPHY TJ, Warsavage TJ, Hebbe AL, Plomondon ME, et al
    Percutaneous Coronary Intervention in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction: Insights from the VA CART Program.
    Am Heart J. 2021 Feb 7. pii: S0002-8703(21)00034.
    PubMed     Abstract available
    
    
    
15. PEREIRA NL, Avram R, So DY, Iturriaga E, et al
    Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry.
    Am Heart J. 2021;232:84-93.
    PubMed     Abstract available
    
    
    
16. BRAIK N, Guedeney P, Behnes M, Desch S, et al
    Impact of chronic total occlusion and revascularization strategy in patients with infarct-related cardiogenic shock: A subanalysis of the culprit-shock trial.
    Am Heart J. 2021;232:185-193.
    PubMed     Abstract available
    
    
    
17. LOTTES AE, Whatley EM, Royce SM, Bertges DJ, et al
    Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessment for peripheral interventional Devices (RAPID) Paclitaxel Pathways Program.
    Am Heart J. 2021;232:71-83.
    PubMed     Abstract available
    
    
    January 2021
18. SAWANO M, Spertus JA, Masoudi FA, Rumsfeld JS, et al
    Bleeding Avoidance Strategies and Percutaneous Coronary Intervention Outcomes: A Ten-year Observation from a Japanese Multicenter Registry: Post-PCI Bleeding Avoidance and Outcomes.
    Am Heart J. 2021 Jan 17. pii: S0002-8703(21)00014.
    PubMed     Abstract available
    
    
    
19. GE Z, Kan J, Gao XF, Kong XQ, et al
    Comparison of intravascular ultrasound-guided with angiography-guided double kissing crush stenting for patients with complex coronary bifurcation lesions: rationale and design of a prospective, randomized and multicenter DKCRUSH VIII trial.
    Am Heart J. 2021 Jan 16. pii: S0002-8703(21)00015.
    PubMed     Abstract available
    
    
    
20. ZHAO Y, Sivaswamy A, Lee MK, Izadnegahdar M, et al
    A Feasibility Study for CODE-MI: High-Sensitivity Cardiac Troponin - Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women.
    Am Heart J. 2021 Jan 15. pii: S0002-8703(21)00012.
    PubMed     Abstract available
    
    
    
21. YANKEY GS, Jackson LR, Marts C, Chiswell K, et al
    African American-Caucasian American Differences in Aortic Valve Replacement in Patients with Severe Aortic Stenosis: Racial Differences in AVR.
    Am Heart J. 2021 Jan 13. pii: S0002-8703(21)00009.
    PubMed     Abstract available
    
    
    
22. THIELE H, Freund A, Gimenez MR, de Waha-Thiele S, et al
    Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock - Design and rationale of the ECLS-SHOCK trial.
    Am Heart J. 2021 Jan 8. pii: S0002-8703(21)00004.
    PubMed     Abstract available
    
    
    
23. MARBACH JA, Wells G, Santo PD, So D, et al
    Acute Kidney Injury after Radial or Femoral Artery Access in ST-Segment Elevation Myocardial Infarction: AKI-SAFARI.
    Am Heart J. 2021 Jan 7. pii: S0002-8703(21)00001.
    PubMed     Abstract available
    
    
    
24. FAGEL ND, Amoroso G, Vink MA, Slagboom T, et al
    An immediate or early invasive strategy in non-ST-elevation acute coronary syndrome: the OPTIMA-2 randomized controlled trial.
    Am Heart J. 2021 Jan 7. pii: S0002-8703(21)00003.
    PubMed     Abstract available
    
    
    
25. VALGIMIGLI M, Cao D, Makkar RR, Bangalore S, et al
    Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
    Am Heart J. 2021;231:147-156.
    PubMed     Abstract available
    
    
    December 2020
26. MALIK AO, Amin A, Kennedy K, Qintar M, et al
    Patient-centered contrast thresholds to reduce acute kidney injury in high-risk patients undergoing percutaneous coronary intervention.
    Am Heart J. 2020 Dec 23. pii: S0002-8703(20)30415.
    PubMed     Abstract available
    
    
    
27. CHOUDHARY R, Kumari V
    Aspirin versus P2Y12 inhibitor-based monotherapy after percutaneous coronary intervention.
    Am Heart J. 2020;230:99.
    PubMed    
    
    
    
28. KUNO T, Ueyama H, Takagi H, Bangalore S, et al
    Choosing between aspirin or P2Y12 monotherapy after short course of DAPT.
    Am Heart J. 2020;230:100.
    PubMed    
    
    
    
29. JOYCE J, O'Leary ET, Mah DY, Harrild DM, et al
    Cardiac resynchronization therapy improves the ventricular function of patients with Fontan physiology.
    Am Heart J. 2020;230:82-92.
    PubMed     Abstract available
    
    
    
30. DE LA PAZ A, Orgel R, Hartsell SE, Pauley E, et al
    Getting cardiogenic shock patients to the right place-How initial intensive care unit triage decisions impact processes of care and outcomes.
    Am Heart J. 2020;230:66-70.
    PubMed     Abstract available
    
    
    November 2020
31. DAYAN V, Myers P
    Comparing apples and oranges and adding inches to meters: Is this the way to conduct rigorous meta-analyses of PCI versus CABG in left main coronary disease?
    Am Heart J. 2020;229:180-181.
    PubMed    
    
    
    
32. KUNO T, Ueyama H, Rao SV, Cohen MG, et al
    Meta-analysis of PCI vs. CABG for left main disease revisited.
    Am Heart J. 2020;229:178-179.
    PubMed    
    
    
    
33. YANNOPOULOS D, Kalra R, Kosmopoulos M, Walser E, et al
    Rationale and methods of the Advanced R(2)Eperfusion STrategies for Refractory Cardiac Arrest (ARREST) trial.
    Am Heart J. 2020;229:29-39.
    PubMed     Abstract available
    
    
    October 2020
34. JAWITZ OK, Stebbins AS, Raman V, Alhanti B, et al
    Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial.
    Am Heart J. 2020 Oct 27. pii: S0002-8703(20)30352.
    PubMed     Abstract available
    
    
    
35. JAWITZ OK, Cox ML, Ranney D, Williams JB, et al
    Outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial.
    Am Heart J. 2020;228:91-97.
    PubMed     Abstract available
    
    
    
36. LI Y, Wang X, Bao D, Liao Z, et al
    Optimal antiplatelet therapy for prevention of gastrointestinal injury evaluated by ANKON magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial.
    Am Heart J. 2020;228:8-16.
    PubMed     Abstract available
    
    
    September 2020
37. BIAGIONI RB, Lopes RD, Agati LB, Sacilotto R, et al
    Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial.
    Am Heart J. 2020;227:100-106.
    PubMed     Abstract available
    
    
    August 2020
38. LAURIDSEN MD, Rorth R, Lindholm MG, Kjaergaard J, et al
    Trends in first-time hospitalization, management, and short-term mortality in acute myocardial infarction-related cardiogenic shock from 2005-2017: A nationwide cohort study.
    Am Heart J. 2020 Aug 27. pii: S0002-8703(20)30242.
    PubMed     Abstract available
    
    
    
39. GUTIERREZ JA, Heizer GM, Jones WS, Rockhold FW, et al
    CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial.
    Am Heart J. 2020;229:118-120.
    PubMed    
    
    
    
40. KANG DY, Ahn JM, Park H, Lee PH, et al
    Comparison of optical coherence tomography-guided versus intravascular ultrasound-guided percutaneous coronary intervention: Rationale and design of a randomized, controlled OCTIVUS trial.
    Am Heart J. 2020;228:72-80.
    PubMed     Abstract available
    
    
    
41. SHLOFMITZ E, Torguson R, Mintz GS, Zhang C, et al
    The IMPact on Revascularization Outcomes of intraVascular ultrasound-guided treatment of complex lesions and Economic impact (IMPROVE) trial: Study design and rationale.
    Am Heart J. 2020;228:65-71.
    PubMed     Abstract available
    
    
    
42. KATZ JN
    Back to the future-Are we ready for a randomized trial of surgical versus percutaneous revascularization in cardiogenic shock?
    Am Heart J. 2020;226:264-266.
    PubMed    
    
    
    July 2020
43. STAHLI BE, Varbella F, Schwarz B, Nordbeck P, et al
    Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease.
    Am Heart J. 2020;228:98-108.
    PubMed     Abstract available
    
    
    
44. PLOUMEN EH, Buiten RA, Doggen CJM, Stoel MG, et al
    New-generation drug-eluting coronary stents in octogenarians: Patient-level pooled analysis from the TWENTE I-IV trials.
    Am Heart J. 2020;228:109-115.
    PubMed     Abstract available
    
    
    
45. LI Y, Jing Q, Wang B, Wang X, et al
    Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of t
    Am Heart J. 2020;228:1-7.
    PubMed     Abstract available
    
    
    
46. YU C, Liu C, Du J, Liu H, et al
    Smartphone-based application to improve medication adherence in patients after surgical coronary revascularization.
    Am Heart J. 2020;228:17-26.
    PubMed     Abstract available
    
    
    
47. SILVAIN J, Cayla G, Beygui F, Range G, et al
    Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study.
    Am Heart J. 2020;225:27-37.
    PubMed     Abstract available
    
    
    June 2020
48. YAN Y, Wang X, Guo J, Li Y, et al
    Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial i
    Am Heart J. 2020;227:19-30.
    PubMed     Abstract available
    
    
    
49. DEN DEKKER WK, Van Mieghem NM, Bennett J, Sabate M, et al
    Percutaneous complete revascularization strategies using sirolimus-eluting biodegradable polymer-coated stents in patients presenting with acute coronary syndrome and multivessel disease: Rationale and design of the BIOVASC trial.
    Am Heart J. 2020;227:111-117.
    PubMed     Abstract available
    
    
    
50. KUNO T, Ueyama H, Takagi H, Bangalore S, et al
    P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials.
    Am Heart J. 2020;227:82-90.
    PubMed     Abstract available
    
    
    
51. KUNO T, Ueyama H, Rao SV, Cohen MG, et al
    Percutaneous coronary intervention or coronary artery bypass graft surgery for left main coronary artery disease: A meta-analysis of randomized trials.
    Am Heart J. 2020;227:9-10.
    PubMed     Abstract available
    
    
    
52. LAMBERT LM, McCrindle BW, Pemberton VL, Hollenbeck-Pringle D, et al
    Longitudinal study of anthropometry in Fontan survivors: Pediatric Heart Network Fontan study.
    Am Heart J. 2020;224:192-200.
    PubMed     Abstract available
    
    
    
53. ERHUN F, Kaplan RS, Narayanan VG, Brayton K, et al
    Are cost advantages from a modern Indian hospital transferable to the United States?
    Am Heart J. 2020;224:148-155.
    PubMed     Abstract available
    
    
    May 2020
54. ARMSTRONG PW, Bogaerts K, Welsh R, Sinnaeve PR, et al
    The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients.
    Am Heart J. 2020;226:140-146.
    PubMed     Abstract available
    
    
    
55. SMILOWITZ NR, Galloway AC, Ohman EM, Rao SV, et al
    Coronary revascularization and circulatory support strategies in patients with myocardial infarction, multi-vessel coronary artery disease, and cardiogenic shock: Insights from an international survey.
    Am Heart J. 2020;225:55-59.
    PubMed     Abstract available
    
    
    
56. MARQUIS-GRAVEL G, Huang Z, Zelenkofske SL, Lincoff AM, et al
    Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial.
    Am Heart J. 2020;223:84-86.
    PubMed    
    
    
    
57. COSTA F, van Klaveren D, Colombo A, Feres F, et al
    A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making.
    Am Heart J. 2020;223:44-47.
    PubMed     Abstract available
    
    
    April 2020
58. GUEDENEY P, Thiele H, Kerneis M, Barthelemy O, et al
    Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial.
    Am Heart J. 2020;225:60-68.
    PubMed     Abstract available
    
    
    
59. LAINE M, Lemesle G, Burtey S, Cayla G, et al
    TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial.
    Am Heart J. 2020;225:19-26.
    PubMed     Abstract available
    
    
    
60. DAN K, Shlofmitz E, Khalid N, Hideo-Kajita A, et al
    Paclitaxel-related balloons and stents for the treatment of peripheral artery disease: Insights from the Food and Drug Administration 2019 Circulatory System Devices Panel Meeting on late mortality.
    Am Heart J. 2020;222:112-120.
    PubMed     Abstract available
    
    
    March 2020
61. YOON YH, Ahn JM, Kang DY, Park H, et al
    Pragmatic trial comparing routine versus no routine functional testing in high-risk patients who underwent percutaneous coronary intervention: Rationale and design of POST-PCI trial.
    Am Heart J. 2020;224:156-165.
    PubMed     Abstract available
    
    
    
62. OSMAN M, Saleem M, Osman K, Kheiri B, et al
    Radial versus femoral access for percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: Trial sequential analysis.
    Am Heart J. 2020;224:98-104.
    PubMed     Abstract available
    
    
    
63. SMILOWITZ NR, Alviar CL, Katz SD, Hochman JS, et al
    Coronary artery bypass grafting versus percutaneous coronary intervention for myocardial infarction complicated by cardiogenic shock.
    Am Heart J. 2020 Mar 12. pii: S0002-8703(20)30080.
    PubMed     Abstract available
    
    
    
64. VLACHOJANNIS GJ, Vogel RF, Wilschut JM, Lemmert ME, et al
    COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial.
    Am Heart J. 2020;224:10-16.
    PubMed     Abstract available
    
    
    
65. VESELKA J
    Consequences of impressive myectomy results in a Center of Excellence: The paradox of evidence-based medicine era.
    Am Heart J. 2020;221:157-158.
    PubMed    
    
    
    
66. G TOTH G, Lansky A, Baumbach A, Kelbaek H, et al
    Validation of the all-comers design: Results of the TARGET-AC substudy.
    Am Heart J. 2020;221:148-154.
    PubMed     Abstract available
    
    
    February 2020
67. DAUBERT MA, White JA, Al-Khalidi HR, Velazquez EJ, et al
    Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era.
    Am Heart J. 2020;223:87-97.
    PubMed     Abstract available
    
    
    
68. SONG L, Tu S, Sun Z, Wang Y, et al
    Quantitative flow ratio-guided strategy versus angiography-guided strategy for percutaneous coronary intervention: Rationale and design of the FAVOR III China trial.
    Am Heart J. 2020;223:72-80.
    PubMed     Abstract available
    
    
    
69. JAWITZ OK, Gulack BC, Brennan JM, Thibault DP, et al
    Association of postoperative complications and outcomes following coronary artery bypass grafting.
    Am Heart J. 2020;222:220-228.
    PubMed     Abstract available
    
    
    
70. D'ASCENZO F, Biole C, Raposeiras-Roubin S, Gaido F, et al
    Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries.
    Am Heart J. 2020;220:108-115.
    PubMed     Abstract available
    
    
    January 2020
71. ROMAGUERA R, Salinas P, Brugaletta S, Gomez-Lara J, et al
    Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) trial: Rationale and study design.
    Am Heart J. 2020;222:174-182.
    PubMed    
    
    
    
72. JEONG YJ, Park K, Kim YD
    Comparison between ticagrelor and clopidogrel on myocardial blood flow in patients with acute coronary syndrome, using 13 N-ammonia positron emission tomography.
    Am Heart J. 2020;222:121-130.
    PubMed     Abstract available
    
    
    
73. KINNAIRD T, Gallagher S, Spratt JC, Ludman P, et al
    Complex high-risk and indicated percutaneous coronary intervention for stable angina: Does operator volume influence patient outcome?
    Am Heart J. 2020;222:15-25.
    PubMed     Abstract available
    
    
    
74. NANNA MG, Peterson ED, Wu A, Harding T, et al
    Age, knowledge, preferences, and risk tolerance for invasive cardiac care.
    Am Heart J. 2020;219:99-108.
    PubMed     Abstract available
    
    
    December 2019
75. PUYMIRAT E, Simon T, de Bruyne B, Montalescot G, et al
    Rationale and design of the Flow Evaluation to Guide Revascularization in Multivessel ST-Elevation Myocardial Infarction (FLOWER-MI) trial.
    Am Heart J. 2019;222:1-7.
    PubMed     Abstract available
    
    
    
76. MCCOY IE, Montez-Rath ME, Chertow GM, Chang TI, et al
    Central venous pressure and the risk of diuretic-associated acute kidney injury in patients after cardiac surgery.
    Am Heart J. 2019;221:67-73.
    PubMed     Abstract available
    
    
    
77. SHLOFMITZ E, Torguson R, Zhang C, Craig PE, et al
    Impact of Intravascular Ultrasound on Outcomes Following PErcutaneous Coronary InterventioN in Complex Lesions (iOPEN Complex).
    Am Heart J. 2019;221:74-83.
    PubMed     Abstract available
    
    
    
78. WILLEMSEN LM, Janssen PWA, Hackeng CM, Kelder JC, et al
    A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery-Rationale and design of the POPular CABG trial.
    Am Heart J. 2019;220:237-245.
    PubMed     Abstract available
    
    
    
79. PATEL DM, Thiessen-Philbrook H, Brown JR, McArthur E, et al
    Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery.
    Am Heart J. 2019;220:253-263.
    PubMed     Abstract available
    
    
    November 2019
80. SUTTER JS, Lokhnygina Y, Daubert JP, Bahnson T, et al
    Safety and efficacy outcomes of left atrial posterior wall isolation compared to pulmonary vein isolation and pulmonary vein isolation with linear ablation for the treatment of persistent atrial fibrillation.
    Am Heart J. 2019;220:89-96.
    PubMed     Abstract available
    
    
    
81. SHAVADIA JS, Granger CB, Alemayehu W, Westerhout CM, et al
    High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction.
    Am Heart J. 2019;220:137-144.
    PubMed     Abstract available
    
    
    May 2019
82. GELMAN A, Carlin JB, Nallamothu BK
    Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) and coronary stents: A case study in the analysis and reporting of clinical trials.
    Am Heart J. 2019;214:54-59.
    PubMed    
    
    
    April 2019
83. ZIMMERMANN FM, De Bruyne B, Pijls NHJ, Desai M, et al
    A protocol update of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial: A comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with
    Am Heart J. 2019;214:156-157.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vascular Surgery is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: